Article
Targeting the translational machinery in gastrointestinal stromal tumors (GIST): a new therapeutic vulnerability.
Scientific reports - 18 May 2022
Lee Donna M, Sun Angela, Patil Sneha S, Liu Lijun, Rao Aparna V, Trent Parker T, Ali Areej A, Liu Catherine, Rausch Jessica L, Presutti Laura D, Kaczorowski Adam, Schneider Felix, Amankulor Nduka M, Shuda Masahiro, Duensing Anette
Abstract excerpt
Although KIT-mutant GISTs can be effectively treated with tyrosine kinase inhibitors (TKIs), many patients develop resistance to imatinib mesylate (IM) as well as the FDA-approved later-line agents sunitinib, regorafenib and ripretinib. Resistance mechanisms mainly involve secondary mutations in the KIT receptor tyrosine kinase gene indicating continued dependency on the KIT signaling pathway. The fact that the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.